{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.3.196","meta":{"versionId":"7","lastUpdated":"2021-05-21T01:00:52.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.196","version":"20210521","name":"Brentuximab Vedotin Injectable","status":"active","date":"2021-05-21T01:00:52-04:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","concept":[{"code":"1147323","display":"brentuximab vedotin 50 MG Injection"}]}]},"expansion":{"identifier":"urn:uuid:35821b85-4813-4008-bbf9-07d43f7717a9","timestamp":"2022-06-10T05:12:25-04:00","total":1,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1147323","display":"brentuximab vedotin 50 MG Injection"}]}}